Antibodies News and Research

RSS

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

The currently developed vaccines against SARS-CoV-2 include the RBD in their immunogen. With a similar objective, a new study developed an RBD protein-based vaccine candidate against the SARS-CoV-2, using self-assembling Helicobacter pylori-bullfrog ferritin nanoparticles as an antigen delivery system. The study is published recently in the journal mBio (by the American Society of Microbiology).

8 Mar 2021

SARS-CoV-2 vaccines modeled on South African variant may offer broad protection against other variants

Researchers in South Africa have submitted evidence that suggests that vaccines modeled on the South African variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) would not only be effective on that strain but would also function well against other variants.

8 Mar 2021

Researchers identify new biomarkers associated with severity of COVID-19

A team of researchers from the CHUM Research Centre has identified new biomarkers associated with the severity of COVID-19 in infected patients.

8 Mar 2021

New academic spin-out based in Finland introduces a nasal spray vaccine against COVID

Rokote Laboratories Finland Ltd., a newly-founded academic spin-out based in Finland is working to develop and introduce to the markets a nasal spray vaccine against COVID.

8 Mar 2021

Data from Israel’s vaccination program suggests Pizer-BioNTech COVID-19 vaccine induces strong host antibody response

A team of scientists from Israel has recently evaluated the efficacy of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine, BNT162b2, in inducing host humoral immune response. The findings reveal that the vaccine is capable of inducing strong anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and that the response varies significantly with age. The study is currently available on the medRxiv* preprint server.

8 Mar 2021

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.

8 Mar 2021

Researchers present fragment-based computational design of antibodies that target structured epitopes

A new study describes a novel fragment-based method to design antibody complementarity determining region (CDR) loops.

8 Mar 2021

Impairments in immune response contribute to severe COVID-19

New research by a team of scientists at University Hospital RWTH Aachen in Germany and Erasmus Medical Centre in The Netherlands characterized changes in CD8+ T cells in response to SARS-CoV-2.

8 Mar 2021

How can physicians distinguish between COVID-19 persistence and SARS-CoV-2 reinfection?

One of the most challenging tasks of physicians has been differentiating between persistent COVID-19 and SARS-CoV-2 reinfection. Recently, a team of researchers analyzed SARS-CoV-2 sequences from the publicly available reports on reinfection and persistence. They further characterized the markers of reinfecting sequences and studied the mutation rate in newly evolved persistent variants.

8 Mar 2021

Monoclonal antibodies can be an effective tool in the global fight against malaria

Scientists at Walter Reed Army Institute of Research, in collaboration the Duke University, have confirmed that monoclonal antibodies can be an effective tool in the global fight against malaria.

8 Mar 2021

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

A monoclonal antibody "cocktail" developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published in the journal Nature Medicine.

5 Mar 2021

New, efficient method facilitates antibody development

In recent years, therapeutic antibodies have transformed the treatment of cancer and autoimmune diseases.

5 Mar 2021

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

A new study details the results from a single dose of the FINLAY FR 1A recombinant dimeric receptor-binding domain (RBD) base vaccine during a phase I clinical trial with 30 COVID-19 convalescents to test its capacity for boosting natural immunity.

5 Mar 2021

A SARS-CoV-2 spike protein adjuvant vaccine candidate produces durable rapid protection in vivo

A recent study reports the safety and high efficacy of an adjuvanted vaccine candidate against SARS-CoV-2 and the complications of COVID-19.

5 Mar 2021

Identification of neutralizing IFNL3 autoantibodies in severe COVID-19 cases

Scientists have recently developed a novel alternative molecular display technology called Molecular Indexing of Proteins by Self Assembly (MIPSA). Their research explains how this technology overcomes the critical disadvantages of PLATO and other full-length protein array technologies.

5 Mar 2021

New COVID-19 variants can evade antibodies that work against original form of the virus

New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic.

5 Mar 2021

SARS-CoV-2 can evade immune response by T-killer cells through mutations

The body's immune response plays a crucial role in the course of a SARS-CoV-2 infection. In addition to antibodies, the so-called T-killer cells, are also responsible for detecting viruses in the body and eliminating them.

5 Mar 2021

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

A new study reports positive outcomes from two new vaccine candidates. The research, led by Axel T. Lehrer from the University of Hawaii at Manoa, studied mice's immune response when administered the CoVaccine HT adjuvant with an insect-cell expressed SARS-CoV-2 spike protein ectodomain.

4 Mar 2021

Novavax COVID-19 vaccine shows efficacy against South African SARS-CoV-2 variant

Researchers in the United States and South Africa report that the NVX-CoV2373 vaccine from Novavax has proved effective at preventing coronavirus disease (COVID-19) caused by the B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently emerged in South Africa.

4 Mar 2021

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Researchers in the United States say the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant – P.1 – that has recently emerged in Brazil shows a worrying level of resistance to neutralization by antibodies.

4 Mar 2021

Antibodies News and Research

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

SARS-CoV-2 vaccines modeled on South African variant may offer broad protection against other variants

Researchers identify new biomarkers associated with severity of COVID-19

New academic spin-out based in Finland introduces a nasal spray vaccine against COVID

Data from Israel’s vaccination program suggests Pizer-BioNTech COVID-19 vaccine induces strong host antibody response

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Researchers present fragment-based computational design of antibodies that target structured epitopes

Impairments in immune response contribute to severe COVID-19

How can physicians distinguish between COVID-19 persistence and SARS-CoV-2 reinfection?

Monoclonal antibodies can be an effective tool in the global fight against malaria

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

New, efficient method facilitates antibody development

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

A SARS-CoV-2 spike protein adjuvant vaccine candidate produces durable rapid protection in vivo

Identification of neutralizing IFNL3 autoantibodies in severe COVID-19 cases

New COVID-19 variants can evade antibodies that work against original form of the virus

SARS-CoV-2 can evade immune response by T-killer cells through mutations

Preclinical study finds immune benefit in unrefrigerated Soligenix coronavirus vaccines

Novavax COVID-19 vaccine shows efficacy against South African SARS-CoV-2 variant

Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

Immunology eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News